The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of capital as two prominent players, Monte Rosa Therapeutics (NASDAQ: GLUE) and Genelux Corporation (NASDAQ: GNLX), launched public offerings. These moves signal
Genelux shares are trading lower by 40.7% during Friday's session. The company announced the pricing of an underwritten offering of 6.875 million shares.
